Skip to content
Screener

Veracyte VCYT Price / earnings

Price / earnings at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
40.9×—
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
44.6×—
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
309.6×+302×
Revvity logo
RevvityRVTY
40.9×-3.5×
Quest Diagnostics logo
Quest DiagnosticsDGX
22.1×+1.0×
Agilent Technologies logo
Agilent TechnologiesA
23.1×-3.1×

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

market cap/net income=29.1×

Based on the most recent quarter.

The source filing: Veracyte’s 10-Q, filed May 6, 2026. Open the filing →

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031

FAQ

What is Veracyte's price / earnings?
Veracyte (VCYT) reported price / earnings of 29.1× in Q1 2026.
How has Veracyte's price / earnings changed year-over-year?
Veracyte's price / earnings decreased by 58.4% year-over-year, from 69.9× to 29.1×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Veracyte's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude